Validation of the first treatment-specific questionnaire for the assessment of patient satisfaction with allergen-specific immunotherapy in allergic patients: The ESPIA questionnaire - 30/05/13
Abstract |
Background |
Satisfaction with treatment is a patient-reported outcome shown to be associated with the patient’s health-related decisions and treatment-related behavior, thereby influencing the chances of successful treatment, and is especially relevant in long-term treatment, such as allergen-specific immunotherapy (AIT).
Objective |
We sought to assess the psychometric properties of the Satisfaction Scale for Patients Receiving Allergen Immunotherapy (ESPIA) questionnaire so as to determine the satisfaction of patients receiving AIT treatment.
Methods |
An observational, longitudinal, multicenter study was performed on patients with allergic rhinitis (AR) undergoing AIT treatment. Sociodemographic, clinical, and patient-centered health outcomes data were gathered at the study visits. Feasibility, reliability, validity, and sensitivity to change of the prevalidated version of the ESPIA questionnaire were assessed.
Results |
Four hundred twenty-nine patients were included (52.2% women, 33.6 years of age, 54.5% of the cases with intermittent AR and 62.5% with moderate AR). Low levels of missing items and ceiling/floor effects were found for the overall score of the ESPIA questionnaire. The overall Cronbach α value and intraclass correlation coefficient were 0.90 and 0.92, respectively. The overall score for the ESPIA questionnaire was strongly associated with months receiving AIT, AR type and intensity, presence of conjunctivitis, self-perceived health status, effect of AR on daily life, and expectations about the AIT treatment. The pattern of correlations obtained with other patient-centered health outcomes was consistent with expectations. The ESPIA questionnaire also showed good sensitivity to change for improved health status.
Conclusion |
The ESPIA questionnaire to assess patient satisfaction with respect to AIT treatment presented satisfactory psychometric properties for its use in clinical practice.
Le texte complet de cet article est disponible en PDF.Key words : Allergy, allergen-specific immunotherapy, satisfaction, questionnaire, validation, reliability
Abbreviations used : AIT, AR, ESPIA, TSS4, VAS
Plan
| Supported by Stallergenes Ibérica, S.A. |
|
| Disclosure of potential conflict of interest: J. L. Justicia and M. A. García are employed by Stallergenes Ibérica. V. Cardona and C. Vidal have consultant arrangements with and have received travel support from Stallergenes. P. Guardia has received grants and consulting fees from Stallergenes. P. Ojeda is on the advisory board for Stallergenes, has consultant arrangements with ALK-Abelló and Reig Jofre, and has received grants from Diater Laboratories and Allergopharma. J. M. Olaguíbel has received travel support and fees for participation in review activities from Stallergenes. J. M. Vega has consultant arrangements with and has received travel support from Stallergenes Iberica. E. Baró has received fees for participation in review activities and payment for writing or reviewing this manuscript from 3D Health Research. |
Vol 131 - N° 6
P. 1539 - juin 2013 Retour au numéro
Article précédent
- Do rapid infant growth and childhood asthma have common developmental origins?
- Diane R. Gold
- Role of fibroblasts in the pathogenesis of atopic dermatitis
- Andreas Berroth, Jochen Kühnl, Nina Kurschat, Agatha Schwarz, Franz Stäb, Thomas Schwarz, Horst Wenck, Regina Fölster-Holst, Gitta Neufang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?